{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:59:46Z","timestamp":1785117586141,"version":"3.55.0"},"reference-count":50,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CURE GABA-A"},{"DOI":"10.13039\/100000065","name":"National Institute of Health","doi-asserted-by":"publisher","award":["NS121718"],"award-info":[{"award-number":["NS121718"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Disease variants in GABR genes encoding \u03b3-aminobutyric acid type A receptor (GABAAR) subunits are major causes of developmental and epileptic encephalopathies (DEEs). There is no effective treatment for these DEEs, although the GABAAR is a major target for antiseizure drugs. We previously identified the therapeutic effect of 4-phenylbutyrate (PBA) in Gabrg2+\/Q390X knockin DEE mice and in this study tested the effect of the drug in GABRA1 variants that encode the \u03b11 subunit of GABAAR. We used a multidisciplinary approach including in silico structural modeling, flow cytometry, patch-clamp recordings and biochemistry in conjunction with differential tagging of the wildtype (WT) and the mutant alleles to evaluate the effect of PBA on rescue of GABAAR subunit expression, surface trafficking, and function in vitro in a heterologous HEK293T cell model and in vivo in Gabra1+\/A322D mice. We found that the \u03b11 subunit expression at both the total level and the cell surface was reduced when the variant \u03b11 protein was present, suggesting reduced functional receptor availability on the cell membrane and synapse. Patch-clamp recordings identified that \u03b11 variants reduced GABA-evoked current amplitude. In silico prediction indicated reduced protein stability for GABRA1 variants by negative \u2206\u2206G values. PBA increased both total and surface expression of WT \u03b11 and \u03b11 variants and improved expression of both WT and variant \u03b11 alleles when these were co-expressed. Importantly, PBA also increased the GABAAR expression in the cortex and thalamus of the Gabra1+\/A322D mice. This study indicates that PBA is a promising treatment option for DEEs associated with GABRA1 mutations. Our previous work has demonstrated that PBA improves proteostasis by enhancing expression of the WT allele, repairing the mutant allele, and reducing endoplasmic reticulum stress in other DEEs associated with GABRG2 and SLC6A1 mutations. Importantly, it can mitigate seizures and improve neurobehavioral phenotypes at behavioral levels. Based on this and our previous work on GABRG2 and SLC6A1 mutations, we propose that PBA holds promise as a common medicine for multiple genetic neurologic disorders that share the proteostasis pathology with a broad clinical application in DEEs.<\/jats:p>","DOI":"10.3390\/cells15151327","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:26:23Z","timestamp":1785115583000},"page":"1327","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["4-Phenylbutyrate Rescue in GABRA1 Variants Associated with Developmental Epileptic Encephalopathies: From Cell and Mouse Models to Humans"],"prefix":"10.3390","volume":"15","author":[{"given":"Ziang (Debbie)","family":"Song","sequence":"first","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-3004","authenticated-orcid":false,"given":"Kirill","family":"Zavalin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangzhen","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7700-016X","authenticated-orcid":false,"given":"Melissa B.","family":"DeLeeuw","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve X.","family":"Hunn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0636-2826","authenticated-orcid":false,"given":"Ria S.","family":"Eda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-4310","authenticated-orcid":false,"given":"Juexin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering and Informatics, Luddy School of Informatics, Computing, and Engineering, Indiana University Indianapolis, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1079-5436","authenticated-orcid":false,"given":"Jing-Qiong","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232, USA"},{"name":"Vanderbilt Kennedy Center, Vanderbilt University, Nashville, TN 37232, USA"},{"name":"Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2022.07.007","article-title":"Genetic variations in GABA metabolism and epilepsy","volume":"101","author":"Feng","year":"2022","journal-title":"Seizure"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eplepsyres.2017.08.013","article-title":"Defects at the crossroads of GABAergic signaling in generalized genetic epilepsies","volume":"137","author":"Kang","year":"2017","journal-title":"Epilepsy Res."},{"key":"ref_3","unstructured":"Czuczwar, S.J. (2022). GABA(A) Receptor Variants in Epilepsy. Epilepsy, Exon Publications."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107621","DOI":"10.1016\/j.eplepsyres.2025.107621","article-title":"Phenylbutyrate for monogenetic epilepsy: Literature review","volume":"217","author":"Stone","year":"2025","journal-title":"Epilepsy Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jb\/mvae048","article-title":"Neurodegenerative diseases associated with the disruption of proteostasis and their therapeutic strategies using chemical chaperones","volume":"176","author":"Sugiyama","year":"2024","journal-title":"J. Biochem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/jamaneurol.2016.0449","article-title":"Molecular Pathogenic Basis for GABRG2 Mutations Associated with a Spectrum of Epilepsy Syn-dromes, from Generalized Absence Epilepsy to Dravet Syndrome","volume":"73","author":"Kang","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/epi.12035","article-title":"mRNA surveillance and endoplasmic reticulum quality control processes alter biogenesis of mutant GABAA receptor subunits associated with genetic epilepsies","volume":"53","author":"Macdonald","year":"2012","journal-title":"Epilepsia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nn.4024","article-title":"The human epilepsy mutation GABRG2(Q390X) causes chronic subunit accumulation and neurodegeneration","volume":"18","author":"Kang","year":"2015","journal-title":"Nat. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107572","DOI":"10.1016\/j.neuropharm.2019.03.015","article-title":"Rescue by 4-phenylbutyrate of several misfolded creatine transporter-1 variants linked to the creatine transporter deficiency syndrome","volume":"161","author":"Kasture","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1038\/s41467-018-06507-4","article-title":"Mechanism-based rescue of Munc18-1 dysfunction in varied encephalopathies by chemical chaperones","volume":"9","author":"Guiberson","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"34048","DOI":"10.1074\/jbc.M702384200","article-title":"Modulation of epithelial sodium channel trafficking and function by sodium 4-phenylbutyrate in human nasal epithelial cells","volume":"282","author":"Planes","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1124\/jpet.107.135186","article-title":"Proinflammatory effect of sodium 4-phenylbutyrate in deltaF508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: Involvement of extracellular signal-regulated protein kinase 1\/2 and c-Jun-NH2-terminal kinase signaling","volume":"326","author":"Roque","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1471-4159.2006.03782.x","article-title":"Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress","volume":"97","author":"Kubota","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/pr050319o","article-title":"Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells","volume":"5","author":"Singh","year":"2006","journal-title":"J. Proteome Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V85.1.43.bloodjournal85143","article-title":"Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial","volume":"85","author":"Collins","year":"1995","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1093\/hmg\/dds247","article-title":"Activation of the stress proteome as a mechanism for small molecule therapeutics","volume":"21","author":"Brose","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V84.1.339.339","article-title":"Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate","volume":"84","author":"Dover","year":"1994","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V82.7.2203.2203","article-title":"Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia","volume":"82","author":"Fibach","year":"1993","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1124\/mol.104.001339","article-title":"Sodium 4-phenylbutyrate protects against cerebral ischemic injury","volume":"66","author":"Qi","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.surg.2005.04.019","article-title":"Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis","volume":"138","author":"Vilatoba","year":"2005","journal-title":"Surgery"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/epi.17779","article-title":"4-Phenylbutyrate promoted wild-type gamma-aminobutyric acid type A receptor trafficking, reduced endoplasmic reticulum stress, and mitigated seizures in Gabrg2(+\/Q390X) mice associated with Dravet syndrome","volume":"65","author":"Shen","year":"2023","journal-title":"Epilepsia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"fcac144","DOI":"10.1093\/braincomms\/fcac144","article-title":"4-Phenylbutyrate restored gamma-aminobutyric acid uptake and reduced seizures in SLC6A1 patient variant-bearing cell and mouse models","volume":"4","author":"Nwosu","year":"2022","journal-title":"Brain Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107708","DOI":"10.1016\/j.eplepsyres.2025.107708","article-title":"4-Phenylbutyrate rescues neurobehavioral phenotypes in SLC6A1-related encephalopathy","volume":"220","author":"Randhave","year":"2025","journal-title":"Epilepsy Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107514","DOI":"10.1016\/j.eplepsyres.2025.107514","article-title":"4-Phenylbutyrate restored GABA uptake, mitigated seizures in SLC6A1 and SLC6A11 microdeletions\/3p-syndrome: From cellular models to human patients","volume":"210","author":"DeLeeuw","year":"2025","journal-title":"Epilepsy Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Grinspan, Z.M., Burr\u00e9, J., Cross, J., Ross, M.E., Stone, A., Basma, N., Gao, K., Kang, J.-Q., Lim, J., and Dubow, E. (2024). 4-Phenylbutyrate for STXBP1 and SLC6A1. Safety, tolerability, seizure, and EEG outcomes. A case series at 2 centers. medRxiv, medRxiv:2024.11.06.24316676.","DOI":"10.1101\/2024.11.06.24316676"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/brain\/awab207","article-title":"Common molecular mechanisms of SLC6A1 variant-mediated neurodevelopmental disorders in astrocytes and neurons","volume":"144","author":"Mermer","year":"2021","journal-title":"Brain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"fcae110","DOI":"10.1093\/braincomms\/fcae110","article-title":"gamma-Aminobutyric acid transporter and GABA(A) receptor mechanisms in Slc6a1(+\/A288V) and Slc6a1(+\/S295L) mice associated with developmental and epileptic encephalopathies","volume":"6","author":"Shen","year":"2024","journal-title":"Brain Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng885","article-title":"Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy","volume":"31","author":"Cossette","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1523\/JNEUROSCI.1301-04.2004","article-title":"The juvenile myoclonic epilepsy GABA(A) receptor alpha1 subunit mutation A322D produces asymmetrical, subunit position-dependent reduction of heterozygous receptor currents and alpha1 subunit protein expression","volume":"24","author":"Gallagher","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1460-9568.2005.04168.x","article-title":"Molecular analysis of the A322D mutation in the GABA receptor alpha-subunit causing juvenile myoclonic epilepsy","volume":"22","author":"Krampfl","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"26390","DOI":"10.1074\/jbc.M110.142299","article-title":"GABA(A) receptor alpha1 subunit mutation A322D associated with autosomal dominant juvenile myoclonic epilepsy reduces the expression and alters the composition of wild type GABA(A) receptors","volume":"285","author":"Ding","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12999","DOI":"10.1073\/pnas.0700163104","article-title":"The GABAA receptor alpha1 subunit epilepsy mutation A322D inhibits transmembrane helix formation and causes proteasomal degradation","volume":"104","author":"Gallagher","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"fcab033","DOI":"10.1093\/braincomms\/fcab033","article-title":"Dravet syndrome-associated mutations in GABRA1, GABRB2 and GABRG2 define the genetic landscape of defects of GABA(A) receptors","volume":"3","author":"Hernandez","year":"2021","journal-title":"Brain Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13041-019-0513-9","article-title":"Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy","volume":"12","author":"Bai","year":"2019","journal-title":"Mol. Brain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1212\/WNL.0000000000003087","article-title":"Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies","volume":"87","author":"Johannesen","year":"2016","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, L., and Liu, X. (2022). Clinical phenotype and genotype of children with GABA(A) receptor alpha1 subunit gene-related epilepsy. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.941054"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chen, W., Ge, Y., Lu, J., Melo, J., So, Y.W., Juneja, R., Liu, L., and Wang, Y.T. (2022). Distinct Functional Alterations and Therapeutic Options of Two Pathological De Novo Variants of the T292 Residue of GABRA1 Identified in Children with Epileptic Encephalopathy and Neurodevelopmental Disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052723"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Demos, M., Guella, I., DeGuzman, C., McKenzie, M.B., Buerki, S.E., Evans, D.M., Toyota, E.B., Boelman, C., Huh, L.L., and Datta, A. (2019). Diagnostic Yield and Treatment Impact of Targeted Exome Sequencing in Early-Onset Epilepsy. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00434"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/epi.13344","article-title":"De novo GABRA1 mutations in Ohtahara and West syndromes","volume":"57","author":"Kodera","year":"2016","journal-title":"Epilepsia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nbd.2015.05.016","article-title":"The developmental evolution of the seizure phenotype and cortical inhibition in mouse models of juvenile myoclonic epilepsy","volume":"82","author":"Arain","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1523\/JNEUROSCI.4512-08.2009","article-title":"Two molecular pathways (NMD and ERAD) contribute to a genetic epilepsy associated with the GABA(A) receptor GABRA1 PTC mutation, 975delC, S326fs328X","volume":"29","author":"Kang","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1523\/JNEUROSCI.4772-08.2009","article-title":"The GABRG2 mutation, Q351X, associated with generalized epilepsy with febrile seizures plus, has both loss of function and dominant-negative suppression","volume":"29","author":"Kang","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"35294","DOI":"10.1038\/srep35294","article-title":"Differential protein structural disturbances and suppression of assembly partners produced by nonsense GABRG2 epilepsy mutations: Implications for disease phenotypic heterogeneity","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Poliquin, S., Nwosu, G., Randhave, K., Shen, W., Flamm, C., and Kang, J.Q. (2024). Modulating Endoplasmic Reticulum Chaperones and Mutant Protein Degradation in GABRG2(Q390X) Associated with Genetic Epilepsy with Febrile Seizures Plus and Dravet Syndrome. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094601"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Nwosu, G.I., Shen, W., Zavalin, K., Poliquin, S., Randhave, K., Flamm, C., Biven, M., Langer, K., and Kang, J.Q. (2023). GABA(A) Receptor beta3 Subunit Mutation N328D Heterozygous Knock-in Mice Have Lennox-Gastaut Syndrome. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098458"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/brain\/awz250","article-title":"Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes","volume":"142","author":"Shi","year":"2019","journal-title":"Brain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1021\/acschemneuro.5c00227","article-title":"Improving Proteostasis of Trafficking-Deficient GABA(A) Receptor Variants by Activating IRE1","volume":"16","author":"Fu","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-3-032-07523-9_11","article-title":"Structure-Function Studies of Pentameric Ligand-Gated Ion Channels: Combining Experimental and Computational Approaches","volume":"1497","author":"Cheng","year":"2026","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuroscience.2013.01.008","article-title":"Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain","volume":"236","author":"Hortnagl","year":"2013","journal-title":"Neuroscience"},{"key":"ref_50","unstructured":"Williams, M.P., Wang, Y.J., Kang, J.Q., Perryman, J.H., and Mu, T.W. (2025). GABRA1 frameshift variants impair GABA(A) receptor proteostasis. bioRxiv, bioRxiv:2024.11.28.625971."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1327\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:29:40Z","timestamp":1785115780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":50,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151327"],"URL":"https:\/\/doi.org\/10.3390\/cells15151327","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}